Gene therapy provides a promising approach for cancer treatment. Earlier studies suggested that poly-L-lysine-modified iron oxide nanoparticles (IONP-PLL) might be a promising gene delivery system that can transfect DNA efficiently in vitro and in vivo. In this study we used IONP-PLL as gene carriers to deliver the NM23-H1 gene, the first suppressor gene of cancer metastasis, to tumor cells in vivo. The intravenous injection of IONP-PLL carrying NM23-H1-GFP plasmid DNA significantly extended the survival time of an experimental pulmonary metastasis mouse model. In the IONP-PLL/NM23-H1-GFP-treated group, metastasis was clearly suppressed compared with the group treated with free NM23-H1-GFP plasmid. Furthermore, this gene therapy combined with cyclophosphamide treatment resulted in longer survival times and greater suppression of metastasis growth. In conclusion, treatment with IONP-PLL nanoparticles incorporating the NM23-H1gene is an efficient gene therapy method, and it is even more effective in combination with chemotherapy. This approach appears to be a promising strategy for treatment of metastatic tumors.
Introduction
Metastasis significantly contributes to mortality in cancer patients and is one of the most difficult challenges in cancer therapy. The combination of progress in molecular biology and the development of therapeutic gene transfer vectors makes gene therapy a promising new method for cancer therapy. 1 Efficient gene delivery and expression of exogenous genes are important requirements for effective gene therapy. Most efforts in the gene therapy field have been focused on cancer treatment, and most of them are based on the use of viral vectors. 2, 3 In spite of their high transduction efficiency, viral vectors are associated with immunogenicity, toxicity and possible mutagenesis of the target cells. 4 Non-viral vectors have become an attractive alternative, [5] [6] [7] but the low efficiency of transfection results in less efficient targeting of genes to the tissue of interest. The lack of an effective and safe gene targeting vector has become the major barrier to the wide application of gene therapy. 8 Recent interest has been focused on nanovectors. [9] [10] [11] Nanovectors have a tripartite constitution featuring a core constituent material, a therapeutic and/or imaging payload and biological surface modifiers. 12 Through the optimization of their size, physical properties and variable surface modifiers, nanovectors can overcome different obstacles to effective and targeted gene therapy. [13] [14] [15] [16] We have developed a non-viral nanovector, IONP-PLL (poly-L-lysine-modified iron oxide nanoparticle), 17 which consists of iron oxide nanoparticles conjugated to poly-L-lysine. An earlier study 18 has shown that IONP-PLL nanoparticles have a diameter of about 58 nm, bind and protect DNA, show high transfection efficiency in vitro and in vivo and are highly biocompatible. IONP-PLL/DNA complexes intraveneously injected into mice are distributed into organs, including the brain, spleen and kidneys, with the most efficient delivery to the lungs. The study showed that IONP-PLL might be used as a gene vector for systemic gene therapy.
The NM23-H1 gene was first classified as a metastasis suppressor gene on the basis of several melanoma cell lines with different invasive potential. 19 However, the metastasis-suppressing ability of the NM23-H1 gene in malignant tumor is still debated. The correlation between reduced expression of the NM23-H1 gene and a higher metastatic potential and worse prognosis has been shown in carcinomas of the breast, 20, 21 liver, 22 lung 23 and prostate. 24 On the contrary, the opposite trend has been reported in thyroid carcinomas, 25 neuroblastoma, 26 and head and neck carcinomas. 27 Obviously, the NM23-H1 protein has a different and possibly variable role in tumors of different origins. Next to its main function as nucleoside diphosphate kinase, 28, 29 NM23-H1 is further shown to interact with many different proteins, some of which are involved in cancer progression.
30 NM23-H1 is reported to co-immunoprecipitate with the KSR protein and to reduce ERK-MAPK activation in response to signaling. [31] [32] [33] Recent studies showed that NM23-H1 and its interacting partner STRAP physically interact with p53 and positively regulate its functions, including p53-induced apoptosis and cell cycle arrest. 34 In this study, we evaluated the inhibition of tumor metastasis in melanoma tumor-bearing mice by delivery of IONP-PLL carrying an expression plasmid with the NM23-H1 gene. The efficacy of the IONP-PLL treatment was tested both in isolation and in combination with conventional chemotherapy.
Results
Characteristics of IONP-PLL and IONP-PLL/DNA complexes IONP-PLL were prepared according to Xiang et al. 17, 18, 35 The structure and dimensions of IONP-PLL/DNA complexes are shown in Figure 1 . IONP-PLL/DNA complexes are 48 ± 14 nm in diameter. At pH 7.0, the z potential of IONP was about À10 mv due to the abundant OH À ions. After IONP were modified with poly-L-lysine, the z potential increased and reached 8 mv at pH 7.0 for IONP-PLL due to the increasing positive charge of (NH 3 ) þ on the magnetic surface.
Exogenous gene distribution in tumor metastatic nodules in a pulmonary metastasis model In a previous study, 18 we defined the organ distribution of the gene expression by using flow cytometry after intravenous injection of IONP-PLL/EGFP-C2 complexes to mice. Single-cell suspensions of organs were prepared and the percentage of GFP-positive cells was assessed. As shown in Figure 2 , the EGFP-C2 was efficiently delivered to lungs, brain, spleen and kidneys, with the most efficient delivery to the lungs. Therefore, we focused our attention on pulmonary metastatic disease. B16F10 melanoma cells were injected into mice through the tail lateral vein, resulting in tiny but visible nodules on the lung surface 3 days after implantation, and 15 days after injection, the nodules were large and showed both hemorrhage and necrosis.
To validate the gene expression in tumor metastatic nodules, tumor tissue sections were analyzed for expression of NM23-H1-GFP in tumor cells and other cells in the tumor microenvironment. As shown in Figure 3 , there is no obvious expression of the NM23-H1 gene in tumor cells and normal lung cells of tumor-bearing mice. On the contrary, strong expression was observed in the tumor cells and other cells of tumor-bearing mice treated with IONP-PLL/pNM23-GFP complexes. Also, reduction of metastatic nodules was observed in treated mice when compared with untreated tumor-bearing mice.
Therapeutic effects of delivery of NM23-H1-GFP alone and in combination with chemotherapy
We studied the suppression of tumor metastasis in the pulmonary metastasis model by delivery of pNM23-GFP plasmid DNA encoding the NM23-H1-GFP fusion protein through IONP-PLL. In addition, we studied combination therapy with cyclophosphamide. Mice were injected with tumor cells and randomized over six different treatment groups. The different treatment groups were as follows: (i) IONP-PLL/pNM23-GFP, (ii) cyclophosphamide, (iii) IONP-PLL/pNM23-GFP þ cyclophosphamide, (iv) empty IONP-PLL, (v) free pNM23-GFP plasmid DNA and (vi) saline. Figure 4 shows the Kaplan-Meier survival curves of all six animal groups after the start of treatment (n ¼ 10). All groups were blinded to the investigators with regard to the treatment given. Disclosure of the different groups occurred at the end of the experiment (100 days). As expected, all the control mice in the saline group died within 28 days with a mean survival of approximately 15 days. Treatment with either empty IONP-PLL or free pNM23-GFP plasmid DNA solution did not result in prolonged survival. Interestingly, treatment with pNM23-GFP-loaded IONP-PLL nanovectors delayed tumor growth and prolonged survival to an average survival of approximately 38 days. This was comparable to the improved survival after treatment with cyclophosphamide, which extended the mean survival to approximately 34 days. Notably, combination treatment with both IONP-PLL/pNM23-GFP and cyclophosphamide further prolonged survival significantly compared with cyclophosphamide treatment alone (Po0.032). In the group receiving both IONP-PLL/ pNM23-GFP and cyclophosphamide, 2 out of 10 mice were alive at the end of the experiment (100 days). In one of these mice, there was no evidence of pulmonary metastasis, and, in the other mouse, only small nodules were observed in the lungs. In another experiment, the size and number of metastatic nodules in the different treatment groups were also evaluated (n ¼ 6). As shown in Figure 5 , the growth of tumor nodules at the surface of the lungs was significantly suppressed after treatment with either cyclophosphamide, IONP-PLL incorporating pNM23-GFP plasmid DNA or with the combination of these two compounds (Po0.05). The number of metastasis nodes in these three test groups was 62.2, 23.9 and 8.9%, respectively, of those in the mice treated with free pNM23-GFP plasmid. Of note, combined use of cyclophosphamide and IONP-PLL incorporating pNM23-GFP allowed more efficient suppression compared with using either cyclophosphamide or IONP-PLL/ pNM23-GFP separately (Po0.05). One of the six mice 
Discussion
Iron oxide nanoparticles are widely studied nanoparticles and have multiple applications in many fields, particularly biotechnology and medicine. Even before the term 'nanotechnology' was popular, iron oxide particles were used to magnetically isolate and purify proteins, DNA, viruses and even whole mammalian cells. Numerous reports showed iron oxide nanoparticles potential application in medical diagnostics, 36 drug and gene targeting, 37 ,38 separation technologies, 39 biosensors 40 and hyperthermia. 41, 42 More recently, iron oxide nanoparticles have been proved to possess an intrinsic enzyme mimetic activity similar to that found in natural peroxidases. 43 We focused our attention on the use of iron oxide nanoparticles in gene delivery.
In earlier studies, 17, 18, 35 we have developed a non-viral vector, IONP-PLL, that could bind and protect DNA when incubated with DNase-I or serum. These particles showed high transfection efficiency in vitro. In vivo, IONP-PLL was shown to efficiently deliver exogenous genes to organs such as lung, spleen, brain and kidney. All tests suggested that IONP-PLL might be an ideal systemic delivery system for gene therapy. In this study, we evaluated the anti-cancer efficiency of IONP-PLL loaded with the NM23-H1-GFP gene in an experimental pulmonary metastasis tumor model.
To investigate the distribution and expression of the NM23-H1-GFP gene delivered by IONP-PLL to tumor tissue, histochemistry for the detection of the NM23-H1-GFP fusion protein was performed.
The results showed that in lung of mice treated with IONP-PLL/pNM23-GFP complexes, there was positive expression of NM23-H1-GFP in tumor cells of metastatic nodules as well as in normal lung cells. These data suggested that IONP-PLL have the ability to deliver the exogenous gene into tumor metastasis nodules and maybe using in gene therapy of cancer metastasis treatment. This phenomenon may be due to the fact that the modified iron oxide nanoparticles can change the microenvironment around cells within a short time and escape from the endosome before lysosomal fusion occurs. 35, 44, 45 Also, transfection of NM23-H1-GFP in normal lung cells was observed but there was no obvious change of normal tissue from the appearance of lung and tissue sections. So, we suggest that overexpressing the NM23-H1 gene in normal cells has no major effect and may help to resist invasive potential of B16 cells.
Therapy of cancer metastasis still remains challenging. In this study, injection of IONP-PLL loaded with pNM23-GFP prolonged survival in a mouse model of pulmonary metastasis by suppressing metastasis formation. This phenomenon resulted not only from the ability of IONP-PLL to prevent enzymatic degradation of plasmid DNA in vivo but also from the long circulation time of the particles, which creates a longer exposure of the tumor. 18 It is noteworthy that the combination treatment of cyclophosphamide and the NM23-H1-GFP gene loaded IONP-PLL induced a more efficient suppression of metastasis and longer survival time of mice. Other researchers also have shown improved antitumoral effects of gene therapy in combination with chemotherapy in animal models. Recently, Sonabend et al. 46 showed that, for treatment of malignant glioma, the combination of BCNU and pmIL-12/PPC led to significantly prolonged survival (95 days compared with 45 days in the control mice).
In conclusion, IONP-PLL can be used to bind and transfer NM23-H1 gene into tumor cells in vivo at physiological conditions. In the mouse model, prolonged survival and suppression of tumor metastasis were observed due to significant improvement of the transgene expression using the IONP-PLL nanoparticles. In combination with cyclophosphamide, the antitumor effects were observed to be enhanced. We suggest that IONP-PLL may be developed for efficient gene delivery for use in future antitumor therapies in the clinic.
Materials and methods

Cell culture, plasmids and animals
The mouse melanoma cell line B16F10 was grown in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37 1C in a 5% CO 2 incubator.
Six-to eight-week-old C57BL/6 mice were obtained from the Department of Laboratory Animal Science of Xiangya School of Medicine. Mice were maintained at room temperature under 40% humidity. The Medical Laboratory Animal Management Committee of Xiangya School of Medicine, Central South University approved all animal procedures.
The plasmid pNM23-GFP 47 encoding the NM23-H1-GFP fusion protein was kindly provided by professor Zhu Yunsong (Department of Molecular Genetics, Shanghai Medical School, Fudan University). This plasmid was constructed using EGFP-N1 plasmid and NM23-H1 gene, which was obtained by reverse transcription-PCR from 95D cells, and termination codon was mutated. Plasmid DNA was isolated by the alkaline lysis method and had an OD 260/280 ratio above 1.8.
Preparation of IONP-PLL and incorporation of plasmid DNA An equal volume of a 30% solution of ammonium hydroxide was added to a solution that contained dextran, ferric chloride hexahydrate and ferrous chloride hexahydrate (w/w ratio of dextran/Fe 2 þ /Fe 3 þ ¼ 39.6: 1. 0:2.7). 17, 18 After incubation at 60 1C for 1 h, the mixture was centrifuged for 15 min at 12000 g. The supernatant was collected and passed through 0.22 mm pore size polycarbonate membrane filters. The resulting products listed above and poly-L-lysine were mixed at equal w/w ratio in distilled water, ultrasonically vibrated for at least 1 h, and centrifuged for 10 min at 12000 g. The supernatant was removed, the precipitate was washed with 150 mM sodium chloride solution, and the precipitate was then resuspended in 150 mM sodium chloride solution.
IONP-PLL was sterilized by filtering through a 0.22 mm pore size membrane filter. IONP-PLL/pNM23-GFP complexes were formed by mixing IONP-PLL and pNM23-GFP plasmid DNA at a 1:2 ratio and dropping 30 mg of IONP-PLL onto 60 mg of plasmid DNA at a concentration of 1 mg ml
À1
. The mixture was incubated for 1 h at room temperature to form the complex.
Characterization of IONP-PLL
A volume of 20 ml of IONP-PLL/pNM23-GFP complexes were applied to copper grids covered with Formvar support, which had been briefly treated in a sputter coater. The grids were then negatively stained for 10 min with 1% uranyl acetate. Electron micrographs were then obtained at Â 20000 magnification.
Analysis of the charge on IONP and IONP-PLL was performed by examining their zeta potentials with ZetaSizer 3000Hsa (Malvern Instruments, MA, USA). The system was calibrated with 50-mv standard as recommended by the manufacturer. Experimental samples (5 ml) were measured six times for 30 s.
Experimental pulmonary metastasis model and exogenous gene distribution in tumor tissue
The B16F10 melanoma cells were injected into the tail vein of C57BL/6 mice at a concentration of 2 Â 10 6 cells/ 200 ml serum-free medium to form experimental pulmonary metastasis. To examine tumor metastasis in the lungs, the tumor-bearing mice were killed 15 days later by cervical dislocation, and the lungs were removed, washed with phosphate-buffered saline, and fixed in 10% formalin aqueous solution at 4 1C. Lungs were then embedded in paraffin and cross-sectioned according to the standard histological procedure. The sections were stained with hematoxylin and eosin. To define the transfection efficiency and distribution of NM23-H1-GFP gene in lung tumor metastasis nodules, sections were immunohistochemically stained with an anti-NM23-H1 antibody. IONP-PLL/pNM23-GFP complexes were formed as described above with 60 mg of DNA. Mice were injected with B16F10 melanoma cells (day 1) and treated with intravenously injected IONP-PLL/pNM23-GFP complexes on days 0, 6 and 13. The mice were killed 15 days after cell injection, and the lungs were removed. The slides were deparaffinized and rehydrated, and antigens were repaired in citrate buffer by microwave. Endogenous peroxidase activity was quenched by 0.3% hydrogen peroxide. Nonspecific binding was blocked with normal serum. The sections were then incubated overnight at 4 1C with rabbit anti-mouse NM23-H1 antibody diluted 1:150 in phosphate-buffered saline and treated with the secondary antibody (horseradish peroxidase labeled goat anti-rabbit antibody, 1:500) for 1 h. Then, the slides were developed and incubated with 3,3 0 -diaminobenzidine in 0.03% hydrogen peroxide for 10 min. The sections were then counterstained with hematoxylin, rinsed, and mounted. The negative controls were performed by substituting the primary antibody with phosphate-buffered saline or non-immune mouse serum. All samples were processed under the same conditions. The immunostained slides were examined by light microscopy and digital images were captured with a Nikon DXM1200 digital camera.
In vivo experiments
For treatment, six groups were assessed: (i) IONP-PLL/ pNM23-GFP, (ii) cyclophosphamide, (iii) IONP-PLL/ pNM23-GFP þ cyclophosphamide, (iv) empty IONP-PLL, (v) free pNM23-GFP plasmid DNA and (vi) saline. These groups were treated with intravenous injections into model mice the day before B16F10 cell injection and once a week for 3 weeks thereafter. IONP-PLL/pNM23-GFP complexes were formed as above with 60 mg of pNM23-GFP plasmid DNA and 30 mg of IONP-PLL. Cyclophosphamide was dissolved in 0.9% salt solution and injected at 100 mg kg
À1
. Group (iii) was treated with a combination of both IONP-PLL/pNM23-GFP complexes and cyclophosphamide. Empty IONP-PLL and free pNM23-GFP plasmid DNA were separately injected with 30 mg of empty IONP-PLL and 60 mg of free PNM23-GFP plasmid DNA.
First, the survival of treated mice was evaluated every day to prepare the survival curve. Six groups of treated tumor-bearing mice (n ¼ 10) were inspected for signs of discomfort or distress on a daily basis, and euthanasia was executed when indicated. Mice that survived 100 days were killed. Survival data were analyzed by Kaplan-Meier analysis, and statistical calculations were performed using the log-rank test and w 2 -test where appropriate.
In another experiment, 36 experimental mice (six treatment groups treated similarly, n ¼ 6) were killed by cervical dislocation 15 days after cell injection, and their lungs were removed to quantify the number of metastases by anatomic microscopy. The number of nodules was expressed as the mean ± s.d., and differences were tested by a two-tailed student's t-test.
